Yoon Sangchul, Kim Eun-Do, Song Min-Suk, Han Soo Jung, Park Tae Kwann, Choi Kyoung Sub, Choi Young-Ki, Seo Kyoung Yul
Department of Ophthalmology, Severance Hospital, Institute of Vision Research, Yonsei University College of Medicine, Seoul, 03722, Republic of Korea.
Department of Ophthalmology, National Medical Center, Seoul, 04564, Republic of Korea.
PLoS One. 2016 Jun 22;11(6):e0157634. doi: 10.1371/journal.pone.0157634. eCollection 2016.
We investigated eyedrop vaccination (EDV) in pre-clinical development for immunological protection against influenza and for potential side effects involving ocular inflammation and the central nervous system (CNS). Live attenuated influenza EDV, CA07 (H1N1), PZ-4 (H1N2) and Uruguay (H3N2), induced both systemic and mucosal virus-specific antibody responses in ferrets. In addition, EDV resulted in a clinically significant protection against viral challenge, and suppression of viral replication in nasal secretion and lung tissue. Regarding safety, we found that administered EDV flow through the tear duct to reach the base of nasal cavity, and thus do not contact the olfactory bulb. All analyses for potential adverse effects due to EDV, including histological and functional examinations, did not reveal significant side effects. On the basis of these findings, we propose that EDV as effective, while being a safe administration route with minimum local side effects, CNS invasion, or visual function disturbance.
我们在临床前开发阶段研究了滴眼疫苗接种(EDV),以实现针对流感的免疫保护,并研究其涉及眼部炎症和中枢神经系统(CNS)的潜在副作用。减毒活流感EDV,CA07(H1N1)、PZ - 4(H1N2)和乌拉圭株(H3N2),在雪貂中诱导了全身和粘膜病毒特异性抗体反应。此外,EDV对病毒攻击产生了具有临床意义的保护作用,并抑制了鼻腔分泌物和肺组织中的病毒复制。关于安全性,我们发现给予的EDV通过泪道到达鼻腔底部,因此不会接触嗅球。所有针对EDV潜在不良反应的分析,包括组织学和功能检查,均未发现明显的副作用。基于这些发现,我们认为EDV是有效的,同时是一种安全的给药途径,具有最小的局部副作用、中枢神经系统侵袭或视觉功能障碍。